Want to see EKTAY full AI Analyst Report?
EKTAY Stock Chart & Stats
$6.37
-$0.10(-1.78%)
At close: 4:00 PM EST
$6.37
-$0.10(-1.78%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume122.00
Average Volume (3M)73.00
Market Cap
$1.86B
Enterprise Value$21.82B
Total Cash (Recent Filing)$3.17B
Total Debt (Recent Filing)$7.30B
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)-1.40
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.92
Price to Sales (P/S)1.26
P/FCF Ratio8.98
Enterprise Value/Market Cap11.72
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda11.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Resilient Cash GenerationStrong operating cash flow and a ~34% surge in free cash flow to ~2.3B provide durable internal funding. That cash buffer supports service delivery, product upgrades, R&D and capital needs despite a reported net loss, preserving operational continuity and flexibility.
Recurring Service/software Revenue ModelElekta’s revenue mix emphasizes recurring service, software licensing and upgrades tied to a long-lived installed base. This creates predictable aftermarket cash flows, high customer switching costs and multi-year relationships that stabilize revenue beyond cyclical system sales.
Stable Product Gross MarginsA roughly 37% gross margin carried through recent years indicates durable product-level economics. Stable manufacturing and pricing power at the gross-margin level mean operating recovery is plausible if SG&A and sales volumes normalize, aiding long-term profit restoration.
Bears Say
Profitability DeteriorationSwinging to a net loss weakens retained earnings and reduces reinvestment capacity. Persistent losses can impair pricing leverage, limit competitive bids for large hospital tenders, and force cost cutting that may hurt service quality and long-term growth prospects.
Rising Leverage And Declining EquityHigher debt-to-equity and falling equity reduce financial flexibility. With leverage rising to ~1.0x, interest and covenant risk increase, constraining capital allocation for R&D, capex or acquisitions and making the firm more sensitive to earnings volatility.
Revenue Weakness And Margin CompressionDeclining revenue and compressed operating margins indicate eroding operating leverage. For a capital-equipment provider, sustained order weakness reduces future installed-base growth, undermining long-term service and upgrade revenue that fund margins and strategic investments.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $1.86B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Aug 27, 2026 which is in 39 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on May 28, 2026. The company reported -$0.247 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.13 which represents an annual dividend yield of 0.21%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of -$0.247 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.986%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
-6.37%
Trailing 12-Months
Asset Growth
-5.57%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors